N
ALNY icon

Natixis’s Alnylam Pharmaceuticals ALNY Stock Holding History

Natixis’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Sell
1,371
-15,705
-92% -$4.74M ﹤0.01% 865
2026
Q1 		$5.65M Sell
17,076
-22,703
-57% -$7.73M 0.02% 407
2025
Q4 		$15.8M Buy
+39,779
New +$17.6M 0.06% 250
2024
Q3 		– Sell
-291
Closed -$70.7K – 953
2024
Q2 		$70.7K Sell
291
-391
-57% -$61.7K ﹤0.01% 765
2024
Q1 		$102K Buy
+682
New +$114K ﹤0.01% 773
2022
Q4 		– Sell
-226,034
Closed -$45.3M – 1080
2022
Q3 		$45.3M Buy
226,034
+218,295
+2,821% +$41.6M 0.21% 80
2022
Q2 		$1.13M Buy
7,739
+5,373
+227% +$762K ﹤0.01% 798
2022
Q1 		$386K Sell
2,366
-101,696
-98% -$15.5M ﹤0.01% 1022
2021
Q4 		$17.6M Buy
104,062
+1,546
+2% +$287K 0.06% 271
2021
Q3 		$19.4M Buy
102,516
+94,044
+1,110% +$17.6M 0.07% 242
2021
Q2 		$1.44M Buy
8,472
+1,961
+30% +$287K 0.01% 570
2021
Q1 		$919K Buy
6,511
+4,525
+228% +$681K ﹤0.01% 845
2020
Q4 		$258K Sell
1,986
-616
-24% -$82.3K ﹤0.01% 973
2020
Q3 		$379K Buy
+2,602
New +$370K ﹤0.01% 633

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis's ALNY Position: Q2 2026 in Review

Natixis reduced its Alnylam Pharmaceuticals (ALNY) stake by 92% in Q2 2026, selling an estimated $4.74M and leaving 1,371 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

Natixis first reported a position in ALNY in Q3 2020 and has held it in 14 quarters since. The position peaked at $45.3M in Q3 2022. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Natixis held 1,371 shares of Alnylam Pharmaceuticals worth $413K as of Q2 2026.
  • Natixis sold 15,705 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.74M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #865 holding.
  • Natixis first reported a position in Alnylam Pharmaceuticals in Q3 2020 and has held it in 14 quarters since.
  • Natixis's Alnylam Pharmaceuticals position peaked at $45.3M in Q3 2022.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.